biotech

biotech Articles

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade.  This level of...
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor...
If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.  According to Forbes, the brothers, each worth an estimated $2.8 billion, run Baker Bros....
The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,...
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management.  The billionaire is a value investor in the vein of...
Despite broader market indexes reaching new highs, driven mainly by tech stock momentum, many companies have faced plummeting valuations due to worsening macroeconomic conditions. The market has...
Holding a promising future due to recent success in the obesity drug market, Eli Lilly (NYSE:LLY) appears to be bound for continued gains. An impressive move higher in LLY stock, with the company’s...
24/7 Wall Street Insights Early cancer detection is the first line of defense in preventing the disease’s progression and reducing fatalities. Wall Street analysts are unanimously bullish on Exact...
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people...
With a recession likely on the way, health care is the place to be in 2023 for long-term investors looking for growth and income. These seven industry leaders offer solid total return potential in a...
Pharmaceutical giant Merck has offered to acquire biopharma firm Imago Biosciences for $1.35 billion.
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Here are a few big biopharma names on which Wall Street is growing more bearish.
A few big biopharma names were on the move Tuesday morning, and analysts were taking their shot at them.
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.